A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations

Completed

• Conditions: Lip Neoplasms; Throat Cancer; Head and Neck Cancers; Lip Cancer; Mouth Cancer

• Registration Number: NCT00186433
• Lead Sponsor: Stanford University

Brief Summary

1. To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients with nasopharyngeal carcinoma (NPC).

2. To relate pretreatment plasma EBV DNA concentration to WHO classification of these tumors both in endemic and non-endemic areas.

3. To determine whether pretreatment plasma EBV DNA can serve as a prognostic factor for both endemic and non-endemic patient populations.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-11
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-16
• Primary Completion: 2013-06
• Study Completion: 2013-06
• Status Verified: 2015-05
• Last Update Submitted: 2015-05-22
• Last Update Posted: 2015-05-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 49

Inclusion Criteria

• Having a new diagnosis of Nasopharyngeal carcinoma.
• Being treated with either radiotherapy or chemoradiotherapy for this condition.

Exclusion Criteria

• Age <18 since NPC is a very rare condition in this age group and may have a different biological behavior
• Patients who are unable to provide informed consents for themselves.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Plasma Epstein-Bar Virus (EBV) DNA concentrations	every 6 months until end of study	measured by quantitative polymerase chain reaction (PCR)

Trial Locations

Locations (1)

Stanford University School of Medicine; 🇺🇸 Stanford, California, United States